Rafael Fridman
Office Address
Department of Pathology540 E. Canfield Ave, Room 8200
Detroit, MI 48201
Position Title
ProfessorLeader of Proteases and Cancer Program of the Barbara Ann Karmanos Cancer Institute
Education Training
Ph.D. (1986): Hebrew University, Jerusalem, Israel
Postdoctoral Fellowship
1987-1990: National Institutes of Health, Bethesda, MD, USA, in the field of Tumor Biology
Areas of Interest
Matrix metalloproteinases, proteases, protease inhibitors, prostate cancer, and bone metastasisPublications
1. Toth M, Hernandez-Barrantes S, Osenkowski P, Bernardo MM, Gervasi DC, Shimura Y, Meroueh O, Kotra LP, Galvez BG, Arroyo AG, Mobashery S, and Fridman R, 2002, Complex pattern of membrane type 1-matrix metalloproteinase shedding regulation by autocatalytic cell surface inactivation of active enzyme, J Biol Chem, 277: 26340-50.
2. Kruger A, Arlt M, Gerg M, Bernardo MM, Kopitz C, Chang M, Mobashery S and Fridman R, 2005, Antimetastatic activity of a novel mechanism-based gelatinase inhibitor, Cancer Res, 65: 3523-6.
3. Sun Q, Weber CR, Sohail A, Bernardo MM, Toth M, Zhao H, Turner JR, and Fridman R, 2007, MT6-MMP is highly expressed in human colon cancer, promotes tumor growth and exhibits unique biochemical properties, J Biol Chem, 282: 21998-2010.
4. Cho J-A, Osenkowski P, Zhao H, Kim S, Toth M, Cole K, Aboukameel A, Saliganan A, Schuger L, Bonfil RD, and Fridman R, 2008, The inactive 44-kDa processed form of MT1-MMP enhances proteolytic activity via regulation of endocytosis of active MT1-MMP, J Biol Chem, 283: 17391-405.
5. Sohail A, Sun Q, Zhao H, Bernardo MM, Cho J-A and Fridman R, 2008, MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer, Cancer Met Rev, 27: 289-302.
Courses taught by Rafael Fridman
Fall Term 2024 (current)
Winter Term 2024
Fall Term 2023
Winter Term 2023
Fall Term 2022
- CHM6680 - Clinical and Molecular Aspects of Cancer
- CHM7680 - Clinical and Molecular Aspects of Cancer